Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04987567
Other study ID # PED-DHA-FQ
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 21, 2018
Est. completion date February 20, 2020

Study information

Verified date June 2021
Source Corporacion Parc Tauli
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates the effect of antioxidant docosahexaenoic acid (DHA) in patients with cystic fibrosis. Half of participants will receive DHA, while the other half will receive placebo.


Description:

Several studies show that patients with cystic fibrosis (CF) usually have, compared to the normal population, low levels of linoleic acid (LA) and docosahexaenoic acid (DHA) and increase in arachidonic acid (AA), which is pro-inflammatory. Normalization or modification of this fatty acid pattern (AP) could reduce chronic inflammation. The aim of this study is to assess the effect of oral supplementation with DHA for one year in pediatric patients (6-18 years) with CF, on inflammatory parameters, AP profile, lung function (spirometry) and number of exacerbations.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date February 20, 2020
Est. primary completion date February 20, 2020
Accepts healthy volunteers No
Gender All
Age group 6 Years to 18 Years
Eligibility Inclusion Criteria: - Patients of both genders with a diagnosis of cystic fibrosis. - FEV1 > 40%. - Age between 6 and 18 years. - Patients who grant their informed consent or whose representative grants informed consent to participate in the study. Exclusion Criteria: - Pregnant or breastfeeding women - Basal oxygen saturation <92% or household supplemental oxygen needs. - Massive hemoptysis - Patients who are not able to follow or who cannot be assessed in the study according to the protocol. - Any circumstance that, at the discretion of the doctor, may involve a clinical risk or harm, the patient's participation in the study or that interferes with the evaluation of the same. - Use of systemic glucocorticoids or in the 4 weeks prior to inclusion in the study. - Use of non-steroidal anti-inflammatory drugs in the 2 weeks prior to inclusion in the study. - Use of investigational drugs or participation in another clinical trial within 30 days prior to inclusion in the study or within the 5 elimination half-lives of the investigational drug. - Be already supplementing with Omega -3, fish oil or DHA

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
ANTIOXIDANT DHA TRIGLYCERIDE (TRIDOCOSAHEXAENOINE-AOX®)
Pearls of DHA (BrudyNen)
PLACEBO (OLIVE OIL)
Pearls manufactured to mimic DHA (BrudyNen).

Locations

Country Name City State
Spain Parc Tauli Hospital Sabadell Barcelona

Sponsors (1)

Lead Sponsor Collaborator
Corporacion Parc Tauli

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline Fatty Acid (FA) profile (percentage) of the erythrocyte membrane at 6 and 12 months After blood sampling, erythrocytes are separated from the plasma by centrifugation (2500 rpm for 15 min) and stored at -80ºC until analysed. The fatty acids composition are analyzed by gas chromatography.
Fatty acid composition (SFA (saturated FA), MUFA (monoinsatured FA), PUFAs N-6 (polyunsaturated FA omega-6) and PUFAS N-3) are mesured as percentage of total fats.
baseline, 6 month and 12 month of treatment (end of study)
Secondary Change from Baseline Serum interleukins at 12 months Serum are obtained by centrifugation of blood samples and frozen at -80ºC until testing.
Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) are analized in serum by enzyme-linked immunosorbent assay (ELISA kits).
baseline and 12 month of treatment (end of study)
Secondary Change from baseline pulmonary function at 3,6 ,9 and 12 months Forced expiratory volume in 1 second (FEV1) , forced vital capacity (FVC) and 25-75% of the forced vital capacity (FEF25-75%) were mesured using spirometry, calibrated daily according to standardized techniques.
The results are expressed as the mean value of the percentage of predicted values according to height and sex and litres (L)
baseline, 3 months, 6 month, 9 months and 12 month of treatment (end of study)
Secondary Number of Pulmonary exacerbation during the study year compared with previous years The investigators will report the number of pulmonary exacerbations during the previous year and the year of the study. To calculate the number of exacerbations, the medical records of the patients will be reviewed. 12 months prior study, 12 months of the study
Secondary Change from baseline fecal calprotectin at the 12 months Calprotectin was measured in fecal samples of the participants. Baseline and 12 months
Secondary Adverse reactions during the study Frequency of occurrence of adverse events related to the study treatment: diarrhea, steatorrhea, abdominal pain, nausea, vomiting, gastroesophageal reflux, fishy taste or hemorrhage. baseline, 3, 6 , 9 and 12 month of treatment (end of study)
Secondary Change from Baseline Esputum interleukins at 6 and 12 months Supernatant induced sputum were frozen at -80ºC until testing. Induced sputum Interleukins (IL)-1 ß, IL-6, IL-8 and tumor necrosis factor (TNF)-a (pg/ml) were analized by enzyme-linked immunosorbent assay (ELISA kits). baseline and 12 months
Secondary Change from baseline differencial cell counts in sputum at 6 and 12 months. An equal volume of sterile dithiothreitol (DTT), freshly diluted to 10% by the addition of sterile saline, was added to the sputum. This step was performed under a Bio-safety hood using sterile technique. The samples were then incubated in a shaking water bath at 37° C for 5-10 min, and gently mixed using a transfer pipette at 5-min intervals. The weight of the remaining sputum mixture was measured, and a further three times the volume of both DTT and phosphate-buffered saline (Dulbecco's; Gibco BRL, Grand Island, NY) were added. The mixture was incubated once again in the 37° C shaking water bath for another 5-10 min to ensure complete homogenization. Ten microliters of the homogenized sputum samples, mixed with Trypan Blue stain, was used to calculate total cell counts, using a standard hemacytometer. A further 0.25-0.50 ml of both samples was used to prepare cytospin slides for differential cell counts. baseline, 6 months and 12 monts
Secondary Change from baseline weight at 3, 6, 9 and 12 months Weight in kilograms (kg) were measured every 3 months. Subjects dressed only in light underwear and shoeless. Baseline, 3,6,9 and 12 months
Secondary Change from baseline height at 3, 6, 9 and 12 months Height was measured with a standardised statdiometer every 3months Baseline, 3,6,9 and 12 months
Secondary Change from baseline body mass index (BMI) at 3, 6, 9 and 12 months BMI was calculate every 3 months. Baseline, 3,6,9 and 12 months
Secondary Change from Baseline FA ratios of the erythrocyte membrane at 6 and 12 months The next fatty acids (FA) ratios were calculated:
Arachidonic acid /eicosapentaenoic acid (ARA/EPA) Arachidonic acid/ docosahexaenoic acid (ARA/DHA) N-3 PUFAS/ALA ( a-linolenic acid) N-6 PUFAS/LA (linoleic acid)
baseline, 6 months and 12 months
See also
  Status Clinical Trial Phase
Completed NCT03637504 - Feasibility of a Mobile Medication Plan Application in CF Patient Care N/A
Active, not recruiting NCT04602468 - Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER) Phase 4
Completed NCT06109675 - Nutritional Status Assessment of Pediatric Cystic Fibrosis Patients and Effect of Nutrition Education on Nutritional Status N/A
Active, not recruiting NCT04392544 - Intestinal Inflammation in CF Patients
Completed NCT04084041 - Efficacy of Simeox Airway Clearance Therapy in Children With Cystic Fibrosis N/A
Not yet recruiting NCT03292718 - Clinical Trial to Assess Influence of MyCyFAPP Use on GI Related QOL in Children With Cystic Fibrosis N/A
Not yet recruiting NCT05493137 - Physical Activity Levels of Parents of Children With Cystic Fibrosis- (PHACTS-CF)
Enrolling by invitation NCT06188988 - Viral Infections and Airway Microbiome in Young Children With Cystic Fibrosis
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Completed NCT04138589 - Effect of Lumacaftor/Ivacaftor in Children With Cystic Fibrosis Homozygote for F508del on Small Airway Function
Completed NCT03579173 - Determinants of Early Cystic Fibrosis Lung Disease
Recruiting NCT05850351 - Virtual Reality Based Tele-Exercises on Exercise Capacity in Cystic Fibrosis N/A
Completed NCT04463628 - Impacts of the Covid-19 Epidemic and Associated Lockdown Measures on the Management, Health and Behaviors of Cystic Fibrosis Patients During the 2020 Epidemic
Completed NCT04835376 - Percussion Palm Cup: Safety and Usability in Infants and Children With Cystic Fibrosis N/A
Completed NCT04293926 - Heart Rate Variability in Children and Adolescents With Cystic Fibrosis N/A
Withdrawn NCT04415268 - Combined Effect of CFTR Protein Modulator Drugs and Exercise in Cystic Fibrosis N/A
Not yet recruiting NCT06066723 - 19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease
Terminated NCT03939065 - Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management N/A
Active, not recruiting NCT04613128 - The PROMISE Pediatric Study 6 to 11 Years Old
Completed NCT06242951 - Cardiopulmonary Fitness in Children With Cystic Fibrosis Compared to Healthy Children